Geoff Meacham

After ending 2019 on an upbeat note, shares of pharma giant Merck & Co., Inc. (NYSE: MRK) have faltered in 2020, and an analyst at BofA Securities delved into probable factors that put the brakes on the rally. The Merck Analyst Geoff Meacham maintained a Neutral rating and $90 price target for...

The 38th annual JPMorgan Healthcare Conference, which is tipped off as the biggest health care investment symposium, kicks off Monday in San Francisco, California. From the high and mighty to the smallest of nanocaps, biopharma and health care companies have scheduled presentations at the four-day...

Seattle Genetics, Inc. (NASDAQ: SGEN) shares are advancing following an early approval for Padcev, an antibody conjugate therapy it is co-developing with Astellas Pharma Inc. (OTC: ALPMY). Seattle Genetics said the FDA has granted accelerated approval for Padcev, or enfortumab vedotin, for the...

United Therapeutics Corporation (NASDAQ: UTHR) may face stiffening competition from generic entrants, which could meaningfully increase pricing pressure and shrink its market share, according to Bank of America Merrill Lynch The UTHR Analyst BofA's Geoff Meacham initiated coverage of...

Biogen Inc (NASDAQ: BIIB) shares rallied strongly Tuesday after the biotech said it plans a regulatory filing for its Alzheimer's drug aducanumab, which the company had written off back in March. The Analysts Morgan Stanley analyst Matthew Harrison maintained an Underweight rating on...

Barclays revised its view of several smaller mid-cap biotech stocks after the first-quarter earnings season, issuing re-ratings Monday for Prothena Corporation PLC (NASDAQ: PRTA) and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN). The Analyst Barclays analyst Geoff Meacham downgraded Prothena...

Strong clinical data from BioXcel Therapeutics Inc (NASDAQ: BTAI)’s two key assets could give the early stage biopharma company a unique play in the neurology and oncology fields, according to Barclays.  The Analyst Analyst Geoff Meacham initiated coverage on BioXcel with an Overweight...

Incyte Corporation (NASDAQ: INCY) traded down 5.5 percent Wednesday despite posting 6-percent revenue and 143-percent earnings per share beat Tuesday. But analysts were more receptive to the quarterly report. BMO Capital raised its price target to $166, Barclays reiterated positive outlook and...

Analysts at Barclays no longer hold a bullish view on Merck & Co., Inc. (NYSE: MRK) due to a now diminished potential for its biggest value driver, Keytruda. The firm's Geoff Meacham downgraded Merck's stock rating from Overweight to Equal Weight with a price target slashed from $72 to $62....

Barclays initiated coverage of the U.S. small- and mid-cap biotechnology industry with a Positive view, as it expects the outperformance of the sector relative to the S&P 500 to continue in the next 12-18 months. The firm's positive opinion was premised on three factors, namely phase 3...

z,pz.Even as Barclays initiated coverage of the U.S. small- and mid-cap biotechnology industry with a positive view, it was bearish on Cascadian Therapeutics Inc (USA) (NASDAQ: CASC) and Zymeworks Inc (NYSE: ZYME). The firm initiated coverage of Cascadian Therapeutics with an Underweight rating...

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)'s stock soared 25 percent after the company reported encouraging phase 2 data. The company's three-drug cocktails showed an improvement in lung function among patients with cystic fibrosis by 9.6 percentage points or more, which was better...

Barclays initiated coverage of Zymeworks Inc (NYSE: ZYME) with an Overweight rating and price target of $20. The company released first-quarter earnings last week, reporting ($1.13) EPS on the quarter with revenue of $0.23 million. Early-Stage, But Potentially Important Zymeworks is a biopharma...

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), a biopharmaceutical company perhaps most known for its Soliris therapy fell more than 3 percent during Monday's trading session. Investors and traders were reacting to a Bloomberg report, which said Alexion's offices in Brazil were raided by...

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading lower by more than 2 percent Wednesday morning after the company's first quarter earnings and revenue fell short of what analysts were expecting. Although Gilead's numbers point to a top-and-bottom line beat, Barclays' Geoff...